22% year-on-year increase of royalty income from antifungal Cresemba®Operating profit of CHF 18.5 million and net profit of CHF 12.1 millionStrengthened balance sheet through non-dilutive repayment of
16.08.2022 - CHF 29 million royalty income (+22.5% year-on-year) reflecting continued commercial success of CresembaContinued improvement of operating cash flow CHF 142 million cash, restricted cash and investments at half-year 2022Full-year 2022 guidance .
CHF 29 million royalty income (+22.5% year-on-year) reflecting continued commercial success of CresembaContinued improvement of operating cash flow CHF 142 million cash, restricted cash and investments
65% year-on-year growth in non-deferred revenue from Cresemba and Zevtera Operating profit of CHF 1.2 million Future strategic focus on anti-infectives.
65% year-on-year growth in non-deferred revenue from Cresemba and Zevtera Operating profit of CHF 1.2 million Future strategic focus on anti-infectives Exploring strategic options to maximize the value